Boston Scientific Corporation $BSX Shares Bought by Plato Investment Management Ltd

Plato Investment Management Ltd boosted its position in Boston Scientific Corporation (NYSE:BSX) by 4.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 22,075 shares of the medical equipment provider’s stock after purchasing an additional 944 shares during the period. Plato Investment Management Ltd’s holdings in Boston Scientific were worth $2,362,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in BSX. Brighton Jones LLC lifted its position in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares during the last quarter. DAVENPORT & Co LLC lifted its position in shares of Boston Scientific by 15.5% during the 1st quarter. DAVENPORT & Co LLC now owns 13,657 shares of the medical equipment provider’s stock valued at $1,378,000 after acquiring an additional 1,828 shares during the last quarter. Private Trust Co. NA lifted its position in shares of Boston Scientific by 11.4% during the 1st quarter. Private Trust Co. NA now owns 2,919 shares of the medical equipment provider’s stock valued at $294,000 after acquiring an additional 299 shares during the last quarter. Novem Group lifted its position in shares of Boston Scientific by 12.2% during the 1st quarter. Novem Group now owns 2,769 shares of the medical equipment provider’s stock valued at $279,000 after acquiring an additional 301 shares during the last quarter. Finally, D.A. Davidson & CO. lifted its position in shares of Boston Scientific by 4.6% during the 1st quarter. D.A. Davidson & CO. now owns 11,536 shares of the medical equipment provider’s stock valued at $1,164,000 after acquiring an additional 504 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. BTIG Research reiterated a “buy” rating and set a $132.00 price objective on shares of Boston Scientific in a research report on Wednesday, October 22nd. Robert W. Baird increased their price objective on Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. Raymond James Financial increased their target price on Boston Scientific from $121.00 to $124.00 and gave the company a “strong-buy” rating in a report on Thursday, July 24th. UBS Group increased their target price on Boston Scientific from $135.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Finally, Morgan Stanley increased their target price on Boston Scientific from $125.00 to $130.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $123.77.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Ellen M. Zane sold 9,990 shares of the stock in a transaction on Monday, October 27th. The shares were sold at an average price of $101.13, for a total transaction of $1,010,288.70. Following the transaction, the director directly owned 27,035 shares of the company’s stock, valued at $2,734,049.55. This represents a 26.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the transaction, the executive vice president directly owned 178,342 shares in the company, valued at $17,561,336.74. The trade was a 21.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 112,891 shares of company stock worth $11,501,887 over the last three months. Company insiders own 0.50% of the company’s stock.

Boston Scientific Trading Up 0.2%

Boston Scientific stock opened at $100.81 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company has a market capitalization of $149.37 billion, a price-to-earnings ratio of 53.91, a PEG ratio of 2.02 and a beta of 0.61. Boston Scientific Corporation has a one year low of $83.38 and a one year high of $109.50. The company’s fifty day moving average price is $100.76 and its two-hundred day moving average price is $102.35.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. The firm had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The business’s quarterly revenue was up 20.3% on a year-over-year basis. During the same period in the prior year, the business posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.